Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | GIPR | P48546 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809221 | 0.92 | MEN1 (0.41) | TP53MDM2MEN1KMT2ANLRP3 | |
| SCHEMBL6805285 | 0.92 | TP53 (0.49) | TP53MDM2KMT2AALDH1A1MAPT | |
| SCHEMBL6804100 | 0.91 | NLRP3 (0.39) | TP53MDM2MEN1KMT2ANLRP3 | |
| SCHEMBL6607403 | 0.90 | NLRP3 (0.43) | TP53MEN1KMT2ANLRP3ALDH1A1 | |
| SCHEMBL6804785 | 0.89 | TP53 (0.38) | TP53MDM2KMT2AALDH1A1MAPT | |
| SCHEMBL6601993 | 0.87 | MEN1 (0.41) | TP53MDM2MEN1KMT2ANLRP3 | |
| SCHEMBL6602643 | 0.85 | KMT2A (0.44) | TP53MDM2MEN1KMT2ANLRP3 | |
| SCHEMBL6600968 | 0.85 | MEN1 (0.43) | TP53MEN1KMT2ANLRP3ALDH1A1 | |
| SCHEMBL6800862 | 0.85 | NLRP3 (0.43) | MEN1KMT2ANLRP3ALDH1A1MAPT | |
| SCHEMBL6601799 | 0.85 | MAPT (0.42) | TP53MDM2MEN1KMT2ANLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-1432689-A1 | PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | Bayer Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027074-A1 | PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | MKI67, CDK4, FLT4 | TP53 35/4885MDM2 1509/4885MEN1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.